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Cordyceps sinensis, a fungus that parasitizes on the larva of Lepidoptera, has been used as a valued
traditional Chinese medicine. We investigated the effects of water extracts of Cordyceps sinensis (WECS),
and particularly focused on its anticancer and antimetastatic actions. Based on in vitro studies, we report
that WECS showed an anticancer action, and this action was antagonized by an adenosine A3 receptor
antagonist. Moreover, this anticancer action of WECS was promoted by an adenosine deaminase in-
hibitor. These results suggest that one of the components of WECS with an anticancer action might be an
adenosine or its derivatives. Therefore, we focused on cordycepin (30-deoxyadenosine) as one of the
active ingredients of WECS. According to our experiments, cordycepin showed an anticancer effect
through the stimulation of adenosine A3 receptor, followed by glycogen synthase kinase (GSK)-3b acti-
vation and cyclin D1 suppression. Cordycepin also showed an antimetastatic action through inhibiting
platelet aggregation induced by cancer cells and suppressing the invasiveness of cancer cells via inhib-
iting the activity of matrix metalloproteinase (MMP)-2 and MMP-9, and accelerating the secretion of
tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 from cancer cells. In conclusion, cordycepin,
an active component of WECS, might be a candidate anticancer and antimetastatic agent.
© 2014 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cordyceps sinensis is a fungus that parasitizes on larvae of
Lepidoptera and has been used as a herbal tonic in traditional
Chinese medicine for over 300 years. Many papers have reported
the diverse pharmacological activities of C. sinensis (1,2). Natural
products of C. sinensis are too rare to obtain and very expensive. In
addition, the content of each component of natural products is
variable and it might be difﬁcult to check their quality. Therefore,
we chose the cultured fruiting body of C. sinensis produced by
Xinhui Xinhan Artiﬁcial Cordyceps Factory (Guangdong, China) and
supplied by Gunsei Co., Ltd. (Tokyo, Japan) as our experimental
material, and investigated the pharmacological effects of hot water
extracts (70 C for 5 min) of C. sinensis (WECS). We investigated the
action of WECS on cancer, particularly on metastasis. As activeogy, School of Pharmacy and
o, Nishinomiya, Hyogo 663-
akamura).
rmacological Society.
. Production and hosting by Elseingredients of WECS, we focused on cordycepin (30-deoxy-
adenosine) and examined its anticancer and antimetastatic effects
and the mechanisms of these effects. It has been reported that
cordycepin interacts in biochemical processes, including nucleic
acid synthesis, platelet aggregation, metastasis, inﬂammatory re-
actions, apoptosis, and cell cycle signaling (3). In this review, we
mainly present our research ﬁndings on cordycepin, as an active
ingredient of WECS.
2. Direct cytotoxicity of WECS against cancer cells via
stimulation of adenosine A3 receptor
In in vitro studies, Nakamura et al. investigated the anticancer
effect of WECS against B16 mouse melanoma (B16) and Lewis lung
carcinoma (LLC) cells, andWECS showed direct cytotoxicity against
both B16 and LLC cells at 10 and 30 mg/mL (4). Nakamura et al.
indicated that WECS (100 mg/mL) induced the apoptosis of B16-F10
mouse melanoma cells after 48-h exposure in vitro, as determined
by both the TdT-mediated dUTP-biotin nick end labeling (TUNEL)
method and the detection of a DNA ladder (5). Lee et al. also
demonstrated that cordycepin induced apoptosis in humanvier B.V. This is an open access article under the CC BY-NC-ND license (http://
K. Nakamura et al. / Journal of Pharmacological Sciences 127 (2015) 53e5654prostate PC-3 cells through a mitochondria-mediated, caspase-
dependent pathway (6). Yoshikawa et al. reported that WECS
(10 mg/mL) markedly inhibited the growth of B16-BL6 mouse
melanoma (B16-BL6) cells, LLC cells, HT1080 human ﬁbrosarcoma
(HT1080) cells, and CW-2 human colon carcinoma (CW-2) cells, and
the inhibitory effect of WECSwas signiﬁcantly antagonized by 1 mM
3-ethyl 5-benzyl 2-methyl-6-phenyl-4-phenylethynyl-1,4-
(±)-dihydropyridine-3,5-dicarboxylate (MRS1191), a selective
adenosine A3 receptor antagonist. Furthermore, WECS included
2.34% w/w cordycepin and 0.12% w/w adenosine as components
according to the HPLC-electrochemical detection (ECD) system (7).
That is, one of the active ingredients of WECS inhibited the prolif-
eration of four cancer cell lines by the stimulation of adenosine A3
receptors, and this active ingredient may be cordycepin and not
adenosine.
3. Cordycepin, an active ingredient of WECS, and its direct
cytotoxicity against cancer cells
In in vitro studies, Nakamura et al. demonstrated that cordyce-
pin showed marked inhibitory effects on the growth curves of B16-
BL6 cells (IC50 ¼ 39 mM) and LLC cells (IC50 ¼ 48 mM), while
adenosine and 20-deoxyadenosine (up to 100 mM) had no effect on
the growth of the two cancer cell lines. Among the adenosine
receptor agonists and antagonists used (up to 100 mM), only 2-
chloro-N6-(3-iodobenzyl)-adenosine-50-N-methyluronamide (Cl-
IB-MECA), a selective adenosine A3 receptor agonist, notably
inhibited the growth of B16-BL6 cells (IC50 ¼ 5 mM) and LLC cells
(IC50 ¼ 14 mM). Furthermore, the cancer growth inhibitory effect of
cordycepin was antagonized by MRS1191 (8). Thus, cordycepin
exerts direct cytotoxicity against mouse melanoma and lung car-
cinoma cells by stimulating adenosine A3 receptors. These results
also support cordycepin as a potent active ingredient of WECS.
4. Promotion of anticancer effects of WECS and cordycepin by
2′-deoxycoformycin (DCF), an adenosine deaminase inhibitor
In in vitro studies, Yoshikawa et al. attempted to elucidate the
combined effect of DCF, an adenosine deaminase inhibitor, with
WECS and cordycepin on the growth curves of B16-BL6 and LLC
cells. As a result, the anticancer effect of WECS on the growth
curves of the two cancer cell lines increased over three-fold in
combination with DCF. In addition, DCF signiﬁcantly promoted the
anticancer effect of cordycepin by approximately three hundred-
fold (9). Consequently, DCF is a potent adjuvant for WECS. In
other words, one of the effective components of WECS is metabo-
lized by adenosine deaminase. These phenomena indicate that
cordycepin may be one of the active components of WECS.
5. Cordycepin exerts an anticancer effect through the
stimulation of adenosine A3 receptor followed by glycogen
synthase kinase-3b (GSK-3b) activation and cyclin D1
suppression
In in vitro studies by Yoshikawa et al., a radioligand binding
assay using [125I]-AB-MECA, a selective adenosine A3 receptor
agonist, revealed that B16-BL6 cells express adenosine A3 receptors
and that cordycepin binds to these receptors. Yoshikawa et al. also
conﬁrmed the involvement of adenosine A3 receptors in the action
of cordycepin using MRS1523 and MRS1220, speciﬁc adenosine A3
receptor antagonists. Next, indirubin, a GSK-3b inhibitor, antago-
nized the growth suppression of B16-BL6 cells induced by cordy-
cepin. Furthermore, the level of cyclin D1 protein in B16-BL6 cells
was decreased by cordycepin based on Western blot analysis (10).
Taken together, cordycepin inhibits the proliferation of mousemelanoma cells by stimulating adenosine A3 receptors followed by
the Wnt signaling pathway, including GSK-3b activation and cyclin
D1 inhibition. Ko et al. demonstrated that cordycepin enhanced
proteasome-dependent degradation and inhibited the nuclear
translocation of b-catenin in U937 human leukemic monocyte
lymphoma (U937) cells. Furthermore, cordycepin-reduced b-cat-
enin stability was restored by the addition of a GSK-3b inhibitor
(SB216763), indicating that this stability is mediated by the acti-
vation of GSK-3b (11). Their results strongly support our ﬁndings.
6. Combined effects of WECS (p.o.) and methotrexate (MTX)
on hematogenous lung metastasis in mice
In in vivo studies, combined treatment with WECS and MTX of
C57BL/6J mice intravenously inoculated with B16-BL6 cells was
conducted.WECS (200 and 500mg/kg) in drinking water was given
to mice from one week before to 20 days after cancer inoculation
(for 27 days). MTX was administered s.c. daily to the mice at a dose
of 15 mg/10 mL/kg for 20 days from the date of cancer inoculation.
Although MTX caused a signiﬁcant and severe decrease in the body
weight compared with that in control mice starting 16 days after
the start of administration, the mice given both MTX andWECS did
not show a signiﬁcant decrease in body weight. The survival time of
mice given the combination of MTX and WECS (200 mg/kg) was
signiﬁcantly longer than that of the control mice (5). WECS might
be beneﬁcial for the prevention of cancer metastasis as an adjuvant
agent in cancer chemotherapy, and it also reduces the adverse ef-
fects of chemotherapeutic agents.
7. Inhibitory effect of WECS (i.p.) on hepatic metastasis of
cancer cells in mice
In in vivo studies, Kubo et al. investigated the antimetastatic
activity of WECS using a mouse model injected with B16-F0 mouse
melanoma (B16-F0) cells into the spleen. WECS (50 mg/kg/day for
20 days after cancer inoculation) administered intraperitoneally
signiﬁcantly reduced the number of metastatic surface nodules of
B16-F0 cells in the liver of C57BL/6Cr mice, and signiﬁcantly pro-
longed their survival. Furthermore, they examined the effect of
WECS on the hepatocyte growth factor (HGF)-accelerated invasion
of B16-F0 cells using a chemo-invasion assay in vitro. WECS (1 mg/
mL) was shown to signiﬁcantly reduce HGF-accelerated B16-F0 cell
invasion (12). Moreover, Kubo et al. investigated the effect of WECS
on tissue inhibitor of metalloproteinase (TIMP)-1 secretion from
B16-F0 cells in order to identify clues to the mechanism underlying
the anti-invasive action of WECS. As a result, WECS (1 mg/mL)
signiﬁcantly increased the secretion of TIMP-1 from B16-F0 cells
(13). These results suggest that WECS has an antimetastatic action
through inhibiting the invasiveness of cancer cells by accelerating
the secretion of TIMP-1 from cells.
8. Anticancer activity of cordycepin (p.o.) in mice
In in vivo studies, the anticancer effect of orally administered
cordycepin was examined in C57BL/6Cr mice inoculated with B16-
BL6 cells. B16-BL6 (1  106) cells were inoculated subcutaneously
into the right footpad of mice. At two weeks after the cell inocu-
lation, the enlarged primary cancer lump was weighed. Cordycepin
(15 mg/kg per day), administered orally to the mice for two weeks
from the date of cancer inoculation, signiﬁcantly reduced the wet
weight of the primary cancer by 36% compared to that of the un-
treated control mice, without any loss of body weight or systemic
toxicity (14). These results show that orally administered cordy-
cepin inhibits melanoma cell growth in mice with no side effects.
Fig. 1. Scheme showing the mechanism of the anticancer effect of cordycepin and its
degradation by adenosine deaminase. A3-R: adenosine A3 receptor (Gi protein coupled
receptor), PKA: cAMP-dependent protein kinase, GSK-3b: glycogen synthase kinase-3b,
DCF: 20-deoxycoformycin.
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of cancer cells in mice
In in vivo studies, Sato et al. investigated the anti-metastatic
activity of cordycepin using a mouse model injected with B16-F0
cells into the spleen. Cordycepin was administered intraperitone-
ally daily at a dose of 0, 0.5, or 5.0 mg/kg for 19 days after cancer
inoculation. All C57BL/6Cr mice inoculated with B16-F0 cells died
due to liver metastasis via the portal vein from the spleen. Cordy-
cepin at 0.5 and 5.0 mg/kg resulted in signiﬁcantly longer survival
times than those observed in control mice (15). Kubo et al. inves-
tigated the effect of cordycepin on TIMP-1 secretion from B16-F0Fig. 2. Scheme showing the mechanism of the antimetastatic effect of cordycepincells in order to identify clues to the mechanism underlying the
anti-invasive action of cordycepin. Cordycepin was shown to
signiﬁcantly accelerate the release of TIMP-1 from cells (13). Jeong
et al. also reported that cordycepin inhibited the expression and
activity of MMP-2 and MMP-9 and simultaneously increased levels
of TIMP-1 and TIMP-2 using LNCaP human prostate carcinoma cells
(16). Taken together, cordycepin may be a potential candidate
antimetastatic agent through inhibiting the activity of MMPs and
accelerating the release of TIMPs from cancer cells.
10. Inhibitory effect of cordycepin (i.v.) on hematogenous
metastasis of cancer cells accelerated by adenosine-5′-
diphosphate (ADP)
In in vivo studies, Yoshikawa et al. investigated whether platelet
aggregation accelerates hematogenous metastasis of B16-F1 mouse
melanoma (B16-F1) cells in C57BL/6Cr mice and the effect of cor-
dycepin on hematogenous metastasis accelerated by ADP. ADP
signiﬁcantly increased the number of metastatic lung nodules in
mice injected intravenously with B16-F1 cells in a dose-dependent
manner, and cordycepin signiﬁcantly reduced the number of met-
astatic nodules of B16-F1 cells formed in the lung accelerated by
ADP injected simultaneously with B16-F1 cells (17). Accordingly,
ADP accelerated hematogenous metastasis and cordycepin had an
inhibitory action on hematogenous metastasis of B16-F1 cells via
the blocking of ADP-induced platelet aggregation in vivo.
11. Activation of Kupffer cell function by WECS (p.o.) in rats
In in vivo studies, Sprague-Dawley rats received a single i.v. in-
jection of a colloidal carbon solution, and then the clearance rate
from the blood was measured. The rats had been administered
WECS p.o. daily at a dose of 200 mg/kg for twenty-ﬁve days until
the day before the injection of colloidal carbon. The half-life of the
colloidal carbon in the blood of rats administeredWECS at 200 mg/
kg was signiﬁcantly shorter than that of the control rats (18). These
results indicate that orally administered WECS activates one of the
immune systems in rats.. MMP: matrix metalloproteinase, TIMP: tissue inhibitor of metalloproteinase.
K. Nakamura et al. / Journal of Pharmacological Sciences 127 (2015) 53e565612. Beneﬁcial effects of WECS and cordycepin on
atherosclerosis in vitro and in vivo (p.o.)
In in vitro studies, Yamaguchi et al. indicated that WECS
exhibited potent antioxidant and antilipid peroxidation activities
and inhibited the accumulation of cholesteryl ester in macrophages
via the suppression of low-density lipoprotein (LDL) oxidation (19).
Furthermore, Yamaguchi et al. showed that WECS administered
orally prevented cholesterol deposition in the aorta of atheroscle-
rotic ICR mice by the inhibition of LDL oxidation mediated by free
radicals rather than by reduction of the serum lipid level (20). Guo
et al. reported that cordycepin administered i.g. at 25 and 50 mg/kg
for twoweeks prevented hyperlipidemia in Syrian golden hamsters
fed a high-fat diet via the activation of AMP-activated protein
kinase (AMPK) (21). In addition, Won et al. demonstrated that
cordycepin injected orally at 10 mg/kg for 14 days attenuated
neointimal formation by inhibiting reactive oxygen species-
mediated responses in vascular smooth muscle cells in Sprague-
Dawley rats (22). Accordingly, cordycepin, as an active ingredient
of WECS, may exert beneﬁcial effects on the formation of athero-
sclerotic lesions induced by oxidative stress.
13. Conclusion
According to our data, cordycepin might be one of the active
ingredients of WECS since the anticancer effect of WECS was
antagonized by MRS1191, MRS1523, and MRS1220, speciﬁc aden-
osine A3 receptor antagonists, and enhanced by the addition of DCF,
an adenosine deaminase inhibitor. We revealed that cordycepin
exhibited an anticancer action through the stimulation of adeno-
sine A3 receptor followed by GSK-3b activation and cyclin D1 sup-
pression (Fig. 1). Cordycepin also showed an antimetastatic action
through the inhibition of platelet aggregation initiated by ADP
released from cancer cells and reduction of the invasiveness of
cancer cells via inhibiting the activity of MMP-2 and MMP-9 and
accelerating the secretion of TIMP-1 and TIMP-2 from those cells
(Fig. 2). Cordycepin, an active component ofWECS, is expected to be
a candidate anticancer and antimetastatic agent.
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